SYNTAX II - Study design


The SYNTAX II Trial is a multicenter, 3-vessel disease, all-comers, open-label, single-arm trial of approximately 450 patients in approximately 25 interventional cardiology centres in Europe. All patients will be treated with an everolimus-eluting stent with a biodegradable abluminal coating.

Comparisons will be undertaken using the completed SYNTAX I Trial as a control: Primary endpoint:comparison with PCI (TAXUS Express).